High-grade B-cell Lymphoma

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

SynKIR-310 for Relapsed/Refractory B-NHL

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Study of SGR-1505 in Mature B-Cell Neoplasms

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)